Table 5.
Multivariate analysis for predictors of long-term survival in ruptured HCC patients who survived >30 days
| Independent factors | HR | 95% CI for HR | P |
|---|---|---|---|
| Modified LCSGJ stage | 0.003 | ||
| Stage II | 1 | ||
| Stage III | 2.1 | 1.1–3.8 | 0.021 |
| Stage IV | 4.3 | 1.8–10.3 | 0.001 |
|
| |||
| Definitive treatment | <0.001 | ||
| Staged hepatectomy | 1 | ||
| Conservative treatment | 9.5 | 3.1–28.7 | <0.001 |
| TAE (TACE) or local ablation | 2.7 | 1.0–7.2 | 0.040 |
HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; LCSGJ, the Liver Cancer Study Group of Japan; TAE, transarterial embolization; TACE, transarterial chemoembolization.